Business
Perimeter Medical Imaging AI Announces Initiation of New Clinical Trial Site at University of Washington/Fred Hutch Cancer Center
Perimeter Medical Imaging AI Announces Initiation of New Clinical Trial Site at University of Was...
About this update from Perimeter Medical Imaging Ai Inc
[{"type":"text","content":"\n \n \n \n Perimeter Medical Imaging AI Announces Initiation of New Clinical Trial Site at University of Washington/Fred Hutch Cancer Center\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n DALLAS\n \n and\n \n TORONTO\n \n \n ,\n \n \n Oct. 31, 2023\n \n \n /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) (\"Perimeter\" or the \"Company\") – a commercial-stage medical technology company – announced the initiation of an additional clinical trial site at the\n \n University of Washington\n \n / Fred Hutch Cancer Center located in\n \n Seattle, WA.\n \n \n \n Perimeter is conducting an ongoing multi-center, randomized two-arm pivotal clinical trial evaluating the investigational Perimeter B-Series OCT combined with its proprietary ImgAssist AI software when used during breast conservation surgeries.\n \n \n \n Meghan R. Flanagan\n \n , MD, MPD,\n \n University of Washington\n \n /Fred Hutch Cancer Center stated, \"Recognizing the unmet need in the field of breast cancer margin visualization, we are pleased to become the most recent site to participate in this clinical study. Combining AI with high-resolution imaging has the potential to become a new standard of care during breast conservation surgery, by reducing the number of repeat surgeries and, ultimately, delivering better outcomes for patients.\"\n \n \n \n Adrian Mendes\n \n , Perimeter's Chief Executive Officer stated, \"We are focused on expediting the development of our next-gen AI technology and its clinical evaluation in an ongoing pivotal trial. Our hope is that the data generated from this study will support the commercialization of Perimeter B-Series, supporting our aim to transform cancer surgery by delivering technology that improves patient outcomes and reduces healthcare costs.\"\n \n \n \n About Perimeter Medical Imaging AI, Inc.\n \n \n \n Based in\n \n Toronto, Canada\n \n and\n \n Dallas, Texas\n \n ,\n \n \n Perimeter Medical Imaging AI\n \n \n (TSX-V: PINK) (OTC: PYNKF) (FSE: 4...